Prosecution Insights
Last updated: November 20, 2026
Application No. 18/070,288

CHLOROPLAST TARGETING PEPTIDES AND CONJUGATES AND COMPOSITIONS THEREOF

Non-Final OA §103
Filed
Nov 28, 2022
Priority
Nov 29, 2021 — provisional 63/283,849
Examiner
SPEED, DEQUANTARIUS JAVON
Art Unit
1663
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
3 (Non-Final)
70%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
21 granted / 30 resolved
+10.0% vs TC avg
Strong +69% interview lift
Without
With
+69.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
37 currently pending
Career history
69
Total Applications
across all art units

Statute-Specific Performance

§101
10.3%
-29.7% vs TC avg
§103
27.8%
-12.2% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
37.8%
-2.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 30 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status 1. Claims 14-16, 18, and 22 are pending and under examination to the extent of the species of a quantum dot, carbon dot, and polyethyleneimine (PEI). Claims 1-13 are canceled. Claims 17 and 19-21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on April 24, 2025. During examination, the Examiner deemed to rejoin the withdrawn species of a quantum dot for examination. Information Disclosure Statement 2. The information disclosure statement (IDS) filed February 06, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS has been considered. A signed copy is attached. Response to Arguments – Claim Rejections - 35 USC § 103 3. Applicant’s arguments and amendments filed September 11, 2026 have overcome the rejections of record. In particular, Applicant’s declaration filed 10/01/2026 has confirmed that the Giraldo-Gomez et al. (US-11186845-B1, published 11/30/2021 (previously cited)) reference upon which the rejections made under 35 USC § 103 depended on was made by an inventor of the instant Application. Therefore, the Giraldo-Gomez reference is disqualified as prior art. However, the claims remain rejected under new grounds of rejection under 35 U.S.C. 103. Claim Rejections - 35 USC § 103 4. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 5. Claims 14-15, 18, and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Santana et al. (Nature Communications. 2020; 11: 2045 (U)) in view of Thagun et al. (Advanced Science. 2019; 6(23):1902064 (previously cited)) and further in view of Chen et al. (Advanced Drug Delivery Reviews. 2013; 65:1357–1369 (previously cited)). Regarding claims 14 and 22, Santana discloses the targeted delivery of nanomaterials with chemical cargoes to chloroplasts (Title; Abstract) and teaches a conjugate comprising one or more polypeptides, one or more nucleic acids, and a functionalized nanoparticle (p. 02, right col, third paragraph; p. 03, Figure 1), wherein the polypeptide comprises the chloroplast-targeting amino acid sequence obtained from the Arabidopsis rubisco bisphosphate carboxylase small chain A (RbcS) protein (i.e., MASSMLSSATMV) and a polypeptide linker amino acid sequence GGC (p. 02, right col, third paragraph; p. 03, Figure 1), wherein the functionalized nanoparticle is a quantum dot (Title; Abstract). Santana also discloses the delivery of DNA into plant cells and organelles via complexing with silica nanoparticles (p. 02, left col, second paragraph). Santana does not teach the entirety of SEQ ID NO:4 and is silent as to whether the recited chloroplast-targeting polypeptide is capable of electrostatically binding to a nucleic acid molecule. However, Applicant’s disclosure notes that SEQ ID NO:4 is comprised of three distinct polypeptide domains: amino acid residues 1-12 (i.e., MASSMLSSATMV; SEQ ID NO:1) were obtained from the Arabidopsis rubisco bisphosphate carboxylase small chain A protein (see Applicant’s specification dated 06/22/2023, p. 09, lns. 3-10); amino acid residues 13-18 comprises a flexible glycine-rich polypeptide linker (see Applicant’s specification dated 06/22/2023, p. 12, lns. 1-14; SEQ ID NO:3); and amino acid residues 19-30 comprise a repetitive positively charged region capable of electrostatically binding to nucleic acid molecules (see Applicant’s specification dated 06/22/2023; p. 11, lns. 1-13; SEQ ID NO:2). Thagun teaches a polypeptide for targeted gene delivery into plastids comprising a chloroplast-targeting polypeptide sequence linked to an amino acid sequence comprising instant SEQ ID NO:2, wherein the sequence comprising instant SEQ ID NO:2 is capable of electrostatically binding to a nucleic acid molecule and the formation of complexes comprising DNA electrostatically bound to the polypeptide (Title; Abstract; pp. 2-3, “2… Formulation of a Plasmid DNA/CTP/CPP Complex for Chloroplast Transformation”, first paragraph). Chen teaches importance of fusion protein linkers in creating stable, bioactive fusion proteins (Abstract), indicates that use of linkers is so routine in the art that linkers can be categorized into three broad categories (i.e., flexible, rigid, and in vivo cleavable linkers); Abstract), and teaches the use of the GGGGGG polypeptide sequence as a flexible linker that increases protein stability and folding (p. 1360, Table 3). The combination of Santana, Thagun, and Chen teaches a conjugate comprising one or more polypeptides, one or more nucleic acids, and a functionalized nanoparticle, wherein the polypeptide comprises the chloroplast-targeting amino acid sequence obtained from the rubisco bisphosphate carboxylase small chain A (RBCSIA) protein (i.e., MASSMLSSATMV), a flexible polypeptide linker (i.e., GGGGGG), and an amino acid sequence that is capable of electrostatically binding to a nucleic acid molecule (i.e., KHKHKHKHKH), wherein the one or more nucleic acids are electrostatically bound to the functionalized nanoparticle, and wherein the functionalized nanoparticle is a quantum dot. The level of ordinary skill in the plant biotechnology art is high as evidenced by both Santana and Thagun. It would have been prima facie obvious to one of ordinary skill in the art to modify the chloroplast-targeting polypeptide taught by Santana with the electrostatic binding sequence taught by Thagun. One of ordinary skill in the art would have been motivated to do so because the targeting polypeptide taught by Santana is obtained from a rubisco subunit and therefore localizes efficiently to the plastids. Furthermore, the chloroplast-targeting sequence taught by Santana is highly conserved among over a dozen crop species (p. 03, Figure 1), which suggests that the sequence will be functional in a large number of plant species. One of ordinary skill in the art would have a reasonable expectation of success that combining the chloroplast-targeting delivery system taught by Santana with the DNA-binding domain taught by Thagun would enhance the ability of both polypeptides to delivery nucleic acids to the plastids of various plant species. One would have been motivated to connect the domains taught by Santana and Thagun with any flexible linker, such as GGGGGG, to improve to the stability of the fusion protein because the use of protein linkers is routine in the art when designing fusions proteins as demonstrated by the extensive review article published by Chen. Accordingly, one of ordinary skill in the art would have been motivated to produce the claimed invention without any surprising or unexpected results. Regarding claim 15, in addition to the teachings discussed above, Santana teaches a conjugate wherein the nucleic acid is DNA (p. 02, left col, second paragraph). Regarding claim 18, Santana teaches a composition comprising the recited conjugate and a carrier (i.e., cyclodextrin; p. 02, right col, third paragraph). Accordingly, one of ordinary skill in the art would have been motivated to produce the claimed invention without any surprising or unexpected results. 6. Claim 16 is rejected under 35 U.S.C. 103 as being unpatentable over Santana et al. (Nature Communications. 2020; 11: 2045 (U)) in view of Thagun et al. (Advanced Science. 2019; 6(23):1902064 (previously cited)), further in view of Chen et al. (Advanced Drug Delivery Reviews. 2013; 65:1357–1369 (previously cited)), and further in view of Duan et al. (Journal American Chemical Society (2007) 129 (11): 3333–3338 (V)). Regarding claim 16, the combined teachings of Santana, Thagun, and Chen are as discussed above. Santana is silent regarding polyethyleneimine (PEI) and ethylenediamine (EDA). However, Duan discloses that coating quantum dots with PEI improves the delivery of quantum dots and nucleic acids into cells (Abstract; p. 3333, second full paragraph) and makes the dots more compact (p. 3335, right col, first full paragraph). The combination of Santana, Thagun, Chen, and Duan renders unpatentable a conjugate comprising one or more polypeptides, one or more nucleic acids, and a functionalized nanoparticle, wherein the polypeptide comprises the chloroplast-targeting amino acid sequence obtained from the rubisco bisphosphate carboxylase small chain A (RBCSIA) protein (i.e., MASSMLSSATMV), a flexible polypeptide linker (i.e., GGGGGG), and an amino acid sequence that is capable of electrostatically binding to a nucleic acid molecule (i.e., KHKHKHKHKH), wherein the one or more nucleic acids are electrostatically bound to the functionalized nanoparticle, wherein the functionalized nanoparticle is a quantum dot, and wherein the functionalized nanoparticle is coated with PEI. The level of ordinary skill in the art is high as evidenced by Santana, Thagun, Chen, and Duan. For the reasons discussed above, it would have been prima facie obvious to combine the teachings of Santana, Thagun, and Chen. One of ordinary skill in the art would have been motivated to do so, because it is well-established in the art that PEI increases the delivery of nucleic acids and quantum dots into cells. Such a modification is routine and trivial for one of ordinary skill in the art and one of ordinary skill would be reasonably motivated to modify the quantum dot taught by Santana with the PEI coating taught by Duan to make an obvious improvement to existing technologies. Accordingly, one of ordinary skill in the art would have been motivated to produce the claimed invention with a reasonable expectation of success and without any surprising or unexpected results. Conclusions 7. No claim is allowed. This action is Non-Final due to Applicant’s declaration filed 10/01/2026, which renders the Giraldo-Gomez reference ineligible as prior art and thus, renders moot the previous rejection under 35 U.S.C. 103. Examiner’s Contact Information 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEQUANTARIUS J SPEED whose telephone number is (703)756-4779. The examiner can normally be reached M-F; 9AM-5PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amjad Abraham can be reached on (571)-270-7058. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEQUANTARIUS JAVON SPEED/Examiner, Art Unit 1663 /Amjad Abraham/SPE, Art Unit 1663
Read full office action

Prosecution Timeline

Nov 28, 2022
Application Filed
Aug 06, 2025
Non-Final Rejection mailed — §103
Feb 06, 2026
Response Filed
Mar 12, 2026
Non-Final Rejection mailed — §103
Sep 11, 2026
Response Filed
Oct 28, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767953
MOGROSIDE COMPOSITIONS AND METHODS OF PRODUCING SAME
3y 1m to grant Granted Oct 20, 2026
Patent 12760319
PLANTS WITH ENHANCED PHOTOSYNTHETIC EFFICIENCY AND BIOMASS YIELD
3y 0m to grant Granted Oct 13, 2026
Patent 12740524
SUNFLOWER SEED
3y 8m to grant Granted Sep 22, 2026
Patent 12733662
MILLET AND FOOD PRODUCTS WITH REDUCED LIPASE ACTIVITY, GENES AND IMPLEMENTATION THEREOF
2y 7m to grant Granted Sep 15, 2026
Patent 12692527
GLUCURONOSYLTRANSFERASE, GENE ENCODING SAME AND METHOD FOR USING THE SAME
3y 11m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
70%
Grant Probability
99%
With Interview (+69.2%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 30 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month